Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Catalent, Inc.

A Comparative Analysis of SG&A Expenses: AstraZeneca PLC vs. Catalent, Inc.

In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants: AstraZeneca PLC and Catalent, Inc., from 2014 to 2023.

AstraZeneca PLC: A Steady Climb

AstraZeneca's SG&A expenses have shown a consistent upward trend, peaking in 2022 with a 95% increase from 2016. This growth reflects the company's strategic investments in marketing and administrative capabilities to support its expanding portfolio.

Catalent, Inc.: A Gradual Rise

Catalent, Inc. has also experienced a rise in SG&A expenses, albeit at a more modest pace. From 2014 to 2023, their expenses increased by approximately 180%, indicating a steady expansion in their operational activities.

Conclusion

While AstraZeneca's expenses are significantly higher, Catalent's growth rate suggests a robust scaling strategy. Missing data for 2024 indicates potential future shifts in these trends.